<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293475</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001012</org_study_id>
    <secondary_id>NCI-2013-00787</secondary_id>
    <secondary_id>CR00022596</secondary_id>
    <secondary_id>HEM-08059-LX</secondary_id>
    <secondary_id>MR00041596</secondary_id>
    <secondary_id>SOL-05025-L</secondary_id>
    <secondary_id>SOL-05025-LM</secondary_id>
    <secondary_id>MR00045915</secondary_id>
    <secondary_id>IRB00001012</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>R01CA137488</secondary_id>
    <nct_id>NCT00293475</nct_id>
  </id_info>
  <brief_title>Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma</brief_title>
  <official_title>A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and
      carboplatin and to see how well they work in treating patients with primary central nervous
      system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping
      them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier
      disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing
      substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may
      block cancer growth in different ways by targeting certain cells. Giving methotrexate,
      mannitol, rituximab, and carboplatin together may be an effective treatment for primary
      central nervous system lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and toxicities of a treatment regimen consisting of rituximab
      (intravenously [IV]) the day prior to methotrexate (intra-arterially [IA]), and carboplatin
      (IA) in conjunction with blood-brain barrier disruption (BBBD) and delayed sodium thiosulfate
      (IV).

      II. To demonstrate, adding a monoclonal antibody and carboplatin to methotrexate BBBD, that a
      45% rate of complete response (CR) within the first 3 months of treatment is achieved, while
      excluding a CR rate as low as 30%.

      SECONDARY OBJECTIVES:

      I. To estimate the response rate (counting all CRs), the two-year overall survival and the
      two-year event-free survival, as baselines for subsequent trials.

      OUTLINE:

      Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10
      minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium
      thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly
      for up to 12 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 2 months, then every 2
      months for 2 years, every 6 months for 1 year, and then annually for at least 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate (Phase II)</measure>
    <time_frame>Within the first 3 months of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of toxicities, assessed using National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 (Phase I)</measure>
    <time_frame>Within 2 months of completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>From entry onto study until death or progression of disease, assessed at 2 years</time_frame>
    <description>Kaplan-Meier estimates of these survival distributions will be plotted. Descriptive stratifications of these survival distributions by baseline characteristics will be evaluated using the log-rank statistic. If there are multiple predictors of these outcomes, Cox proportional hazard models will be fit to these data to determine which predictors are independent of others in a multi-variable model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From entry onto study until death from any cause, assessed at 2 years</time_frame>
    <description>Kaplan-Meier estimates of these survival distributions will be plotted. Descriptive stratifications of these survival distributions by baseline characteristics will be evaluated using the log-rank statistic. If there are multiple predictors of these outcomes, Cox proportional hazard models will be fit to these data to determine which predictors are independent of others in a multi-variable model.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IA</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Given IA</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>D-Mannitol</other_name>
    <other_name>Mannitol, D-</other_name>
    <other_name>Osmitrol</other_name>
    <other_name>Resectisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IA</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab, mannitol, methotrexate, carboplatin)</arm_group_label>
    <other_name>Cyanide Antidote Package</other_name>
    <other_name>Disodium Thiosulfate</other_name>
    <other_name>S-Hydril</other_name>
    <other_name>Sodium Hyposulfate</other_name>
    <other_name>Sodium Thiosulfate Pentahydrate</other_name>
    <other_name>Sodium Thiosulphate</other_name>
    <other_name>Sodothiol</other_name>
    <other_name>Thiosulfate, Sodium, Pentahydrate</other_name>
    <other_name>Thiosulfuric Acid Disodium Salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with histopathologic confirmation of intermediate or high-grade primary
             central nervous system lymphoma (PCNSL) as documented by brain biopsy, or cytology
             (analysis from cerebral spinal fluid [CSF] or vitrectomy), and cluster of
             differentiation 20 (CD20) positive; whenever possible, the tumor should be
             characterized by immunophenotype

          -  Subjects must be =&lt; 90 days from diagnosis of PCNSL in the brain or spine; time from
             pathologic diagnosis to initiation of treatment should be specified; subjects with
             history of only ocular lymphoma are eligible if &lt; 90 days since documented brain
             parenchymal disease (by imaging or by biopsy)

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance score =&lt; 3
             (Karnofsky &gt;= 30)

          -  Hematocrit &gt;= 25% (may be reached by transfusion)

          -  White blood cell count &gt;= 2.5 x 10^3/mm^3

          -  Absolute granulocyte count &gt;= 1.2 x 10^3/mm^3

          -  Platelets &gt;= 100 x 10^3/mm^3 (or &gt;= lower limit of institutional normal value)

          -  Calculated creatinine clearance (Cr Cl) &gt;= 50 ml/min; eligible for full dose
             methotrexate

          -  Calculated Cr Cl &gt;= 30 ml/min; eligible for reduced dose methotrexate

          -  Bilirubin =&lt; 2.0 x upper limit of institutional normal value

          -  The subject may have had other systemic chemotherapy for PCNSL during the 90 days
             since PCNSL diagnosis; prior systemic chemotherapy must have been given at least 4
             weeks prior to study entry (6 weeks for nitrosourea agents), with the exceptions of
             methotrexate and rituximab which may have been given at least 10 days prior; ocular
             lymphoma treatment may have been given any time prior to study entry; if the subject
             has undergone treatment for parenchymal disease and the parenchymal disease has
             progressed on a stable or increasing dose of steroids, the subject is not eligible for
             enrollment

          -  Sexually active women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             treatment and for the duration of study treatment; should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately

          -  Subjects with a bone marrow biopsy which shows microscopic, low-level involvement of
             lymphoma are eligible

          -  Subject with seropositivity for hepatitis B or hepatitis C must be cleared by
             hepatology service prior to participating in treatment protocol

        Exclusion Criteria:

          -  Prior cranial or spinal radiotherapy

          -  Subjects with radiographic signs of excessive intra-cranial mass effect with
             associated rapid neurologic deterioration, and/or spinal block, are unsafe to undergo
             BBBD chemotherapy and are not eligible

          -  Uncontrolled (over the last 30 days), clinically significant confounding medical
             conditions

          -  Seropositivity for the human immunodeficiency virus

          -  Systemic lymphoma

          -  Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or
             lactating are ineligible

          -  Known allergy to any of the study agents

          -  Subjects who are at significant risk for general anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Neuwelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Hospital - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert E. Albright</last_name>
      <phone>859-301-5473</phone>
      <email>darla.hehman@stelizabeth.com</email>
    </contact>
    <investigator>
      <last_name>Robert E. Albright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Peereboom</last_name>
      <phone>216-445-6068</phone>
      <email>peerebd@ccf.org</email>
    </contact>
    <investigator>
      <last_name>David M. Peereboom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward A. Neuwelt</last_name>
      <phone>503-494-5626</phone>
      <email>neuwelte@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Edward A. Neuwelt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward A. Neuwelt</last_name>
      <phone>503-494-5626</phone>
      <email>neuwelte@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Edward A. Neuwelt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

